GlassScriptPhysician profile
Hannah E Moorhead
NPI 1801469556
$4,161.99
in general payments reported to CMS, 2019-2025
35 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.27 · 2023: $1,596 · 2024: $2,131 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,120.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $587.57 | 2023-2025 | |
| Lilly USA, LLC | $489.52 | 2022-2024 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $471.27 | 2023-2025 | |
| Novo Nordisk INC | $417.70 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $362.19 | 2023-2024 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $321.14 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $209.65 | 2023-2025 | Repatha, Krystexxa, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.23 | 2023-2025 | Jardiance |
| Astellas Pharma US INC | $171.26 | 2023-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $153.12 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $109.80 | 2023-2024 | Watchman Flx, Wavewriter Alpha Prime 16, Spectra Wavewriter |
| Xeris Pharmaceuticals, INC. | $64.07 | 2023-2024 | Keveyis |
| Otsuka America Pharmaceutical, INC. | $56.84 | 2024 | Rexulti |
| Mylan Specialty L.P. | $43.82 | 2024 | Yupelri |
| Medtronic, INC. | $36.78 | 2023 | Intellis Adaptivestim |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $36.62 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $33.87 | 2024 | Pyrukynd |
| Biocryst US Sales Co., LLC | $33.35 | 2024 | Orladeyo |
| Mayne Pharma Commercial LLC | $30.11 | 2024 | |
| Seqirus USA INC | $26.66 | 2025 | Fluad, Flucelvax |
| Sumitomo Pharma America, INC. | $26.52 | 2024 | Gemtesa |
| Cashflow Solutions, LLC | $26.40 | 2023 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Vanda Pharmaceuticals INC. | $26.21 | 2025 | Fanapt, Hetlioz |
| Kyowa Kirin, INC. | $25.44 | 2023 | Crysvita |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.50 | 2025 | Caplyta |
| Edwards Lifesciences Corporation | $24.40 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Horizon Therapeutics Plc | $24.23 | 2023 | Krystexxa |
| Idorsia Pharmaceuticals US INC | $22.48 | 2023 | Quviviq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.23 | 2024 | |
| Abiomed | $21.85 | 2025 | |
| Esperion Therapeutics, INC. | $20.87 | 2024 | Nexletol |
| Corcept Therapeutics | $17.80 | 2024 | Korlym |
| Lundbeck LLC | $16.13 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $13.22 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Axsome Therapeutics, INC. | $13.14 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Moorhead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.